JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES) ›› 2017, Vol. 55 ›› Issue (9): 23-30.doi: 10.6040/j.issn.1671-7554.0.2017.145

Previous Articles     Next Articles

The therapeutic efficacy of a potent KSP inhibitor S(MeO)TLC against docetaxel-resistant prostate cancer

DONG Wei1, XING Naidong2, LÜ Jiaju1, LIU Shuai1, SUN Liang1, CAO Qingwei1, DONG Yuhao1, LIU Zhao1, DING Sentai1   

  1. 1. Department of Urology, Shandong Provincial Hospital Affiliated to Shandong University, Jinan 250021, Shandong, China;
    2. Department of Urology, Qilu Hospital of Shandong University, Jinan 250012, Shandong, China
  • Received:2017-02-17 Online:2017-09-10 Published:2017-09-10

PDF (PC)

293

Abstract: Objective To investigate the therapeutic effect of S(MeO)TLC which targetedly inhibits KSP(Eg5)on docetaxel-resistant prostate cancer in vitro. Methods Docetaxel-resistant PC3 cells(PC3R)were developed by chronic, repeated exposure to docetaxel through gradient culture. IC50 of docetaxel-resistant cells to docetaxel was assessed with MTT assay. KSP expressions of different prostate cancer cell lines(PC3, DU145, PC3R)were examined with Western blotting. The cells were divided into control group, PC3 group and PC3R group, and the anti-proliferative activity of S(MeO)TLC was analyzed with MTT and trypan blue staining. After that, the PC3R cells were divided into 山 东 大 学 学 报 (医 学 版)55卷9期 -董伟,等.靶向抑制有丝分裂驱动蛋白治疗多西紫杉醇耐药前列腺癌的体外疗效 \=-control group and S(MeO)TLC group, and the apoptosis was investigated with Hoechst nuclear staining, flow cytometry and RT-PCR in vitro. Results The expressions of KSP in PC3, DU145, and PC3R were similar, with no statistical difference(P>0.05). There was no significant difference in IC50 between PC3R(120 nmol/L)and PC3(106 nmol/L)(P>0.05). After S(MeO)TLC treatment for 24 hours, 87.9% PC3R cells were in the mitosis phase, most of which went apoptosis after 72 hours of S(MeO)TLC treatment. Compared with the control group, PC3R group had significantly increased expressions of Caspase-3(t=13.445, P=0.000 2), Caspase-8(t=9.494, P=0.000 7), Caspase-9(t=5.198, P=0.007), PARP(t=19.097, P=0.000 04), LC3(t=22.609, P=0.000 02)and Beclin1(t=61.266, P=0.000 000 4). Conclusion The resistance of prostate cancer to docetaxel is not related to KSP expression. S(MeO)TLC, as a new KSP/Eg5 inhibitor, has shown obvious anticancer efficacy in docetaxel-resistant prostate cancer cell lines in vitro by inducing cell apoptosis, in which both endogenous and exogenous caspase-dependent apoptotic pathways play an important role, while autophagy plays a synergistic role.

Key words: Kinesin spindle protein, Docetaxel-resistant, Prostate cancer, Targeted therapy

CLC Number: 

  • R737.25
[1] Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016[J]. CA Cancer J Clin, 2016, 66(1): 7-30.
[2] 叶定伟, 朱耀. 中国前列腺癌的流行病学概述和启示[J]. 中华外科杂志, 2015, 53(4): 249-252. YE Dingwei, ZHU Yao. Epidemiology of prostate cancer in China: an overview and clinical implication[J]. Chin J Surg, 2015, 53(4): 249-252.
[3] Armstrong AJ, George DJ. Optimizing the use of docetaxel in men with castration-resistant metastatic prostate cancer[J]. Prostate Cancer Prostatic Dis, 2010, 13(2): 108-116.
[4] Beer TM, Pierce WC, Lowe BA, et al. Phase II study of weekly docetaxel in symptomatic androgen-independent prostate cancer[J]. Ann Oncol, 2001, 12(9): 1273-1279.
[5] 韩博, 戚美, 谭薇薇. 去势抵抗性前列腺癌的发生发展机制及药物治疗新进展[J]. 山东大学学报(医学版), 2015, 53(9): 1-7. HAN Bo, QI Mei, TAN Weiwei. Castration-resistant prostate cancer: current understanding of mechanisms and emerging novel agents[J]. Journal of Shandong University(Health Sciences), 2015, 53(9): 1-7.
[6] 萧畔. 多西紫杉醇诱导前列腺癌PC-3细胞凋亡及耐药前后的蛋白质组学研究[D]. 济南: 山东大学, 2012.
[7] Nakai R, Iida S, Takahashi T, et al. K858, a novel inhibitor of mitotic kinesin Eg5 and antitumor agent, induces cell death in cancer cells[J]. Cancer Res, 2009, 69(9): 3901-3909.
[8] Hayashi N, Koller E, Fazli L, et al. Effects of Eg5 knockdown on human prostate cancer xenograft growth and chemosensitivity[J]. Prostate, 2008, 68(12): 1283-1295.
[9] Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013[J].CA Cancer J Clin, 2013, 63(1): 11-30.
[10] Ding S, Nishizawa K, Kobayashi T, et al. A potent chemotherapeutic strategy for bladder cancer:(S)-methoxy-trityl-L-cystein, a novel Eg5 inhibitor[J]. J Urol., 2010, 184(3): 1175-1181.
[11] Xing ND, Ding ST, Saito R, et al. A potent chemotherapeutic strategy in prostate cancer: S-(methoxytrityl)-L-cysteine, a novel Eg5 inhibitor[J]. Asian J Androl, 2011, 13(2): 236-241.
[12] Ding S, Xing N, Lu J, et al. Overexpression of Eg5 predicts unfavorable prognosis in non-muscle invasive bladder urothelial carcinoma[J]. Int J Urol, 2011, 18(6): 432-438.
[13] Sun L, Lu J, Niu Z, et al. A potent chemotherapeutic strategy with Eg5 inhibitor against gemcitabine resistant bladder cancer[J]. PLoS One, 2015, 10(12): e0144484. doi: 10.1371/journal.pone.0144484. eCollection 2015.
[14] 邢乃栋. 新型Eg5靶向抑制剂S-(methoxytrityl)-L-cysteine治疗前列腺癌的实验研究[D].济南: 山东大学, 2012.
[15] 杨美香. 低氧微环境对树突状细胞功能调控及其作用机制的研究[D]. 济南: 山东大学, 2010.
[16] 卢正磊, 任维华, 荚卫东, 等. 驱动蛋白Eg5在肝细胞癌中的表达及其意义[J].安徽医科大学学报, 2012, 47(9): 1091-1094. LU Zhenglei, REN Weihua, JIA Weidong, et al. The expression and significance of kinesin Eg5 in hepatocellular carcinoma[J]. Acta Universitatis Medicinalis Anhui, 2012, 47(9): 1091-1094.
[17] Wallace TJ, Torre T, Grob M, et al. Current approaches, challenges and future directions for monitoring treatment response in prostate cancer[J]. J Cancer, 2014, 5(1): 3-24.
[18] Ferlay J, Soerjomataram I, Dikshit R, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012[J]. Int J Cancer, 2015, 136(5): 359-386.
[19] Chen W, Zheng R, Baade PD, et al. Cancer statistics in China, 2015[J]. CA Cancer J Clin, 2016, 66(2): 115-132.
[20] Climent MÁ, León-Mateos L, González Del Alba A, et al. Updated recommendations from the Spanish Oncology Genitourinary Group for the treatment of patients with metastatic castration-resistant prostate cancer[J]. Crit Rev Oncol Hematol, 2015, 96(2): 308-318.
[21] Rao S, He L, Chakravarty S, et al. Characterization of the Taxol binding site on the microtubule. Identification of Arg(282)in beta-tubulin as the site of photo incorporation of a 7-benzophenone analogue of Taxol[J]. J Biol Chem, 1999, 274(53): 37990-37994.
[22] Giannakakou P, Gussio R, Nogales E, et al. A common pharmacophore for epothilone and taxanes: molecular basis for drug resistance conferred by tubulin mutations in human cancer cells[J]. Proc Natl Acad Sci U S A, 2000, 97(6): 2904-2909.
[23] Geney R, Ungureanu M, Li D, et al. Overcoming multidrug resistance in taxane chemotherapy[J]. Clin Chem Lab Med, 2002, 40(9): 918-925.
[24] Mozzetti S, Ferlini C, Concolino P, et al. Class III beta-tubulin overexpression is a prominent mechanism of paclitaxel resistance in ovarian cancer patients[J]. Clin Cancer Res, 2005, 11(1): 298-305.
[25] Pronk LC, Hilkens PH, van den Bent MJ, et al. Corticosteroid co-medication does not reduce the incidence and severity of neurotoxicity induced by docetaxel[J]. Anticancer Drugs, 1998, 9(9): 759-764.
[26] Daneshmand S, Quek ML, Lin E, et a1. Glucose-regulated protein GRP78 is up-regulated in prostate cancer and correlates with recurrence and survival[J]. Hum Pathol, 2007, 38(10): 1547-1552.
[27] Ma Y, Miao Y, Peng Z, et al. Identification of mutations, gene expression changes and fusion transcript by whole transcriptome RNAseq in docetaxel resistant prostate cancer cells[J]. Springerplus, 2016, 5(1): 1861.
[28] Sekino Y, Oue N, Shigematsu Y, et al. KIFC1 induces resistance to docetaxel and is associated with survival of patients with prostate cancer[J]. Urol Oncol, 2017, 35(1): e13-31.
[29] Mayer MJ, Klotz LH, Venkateswaran V. The effect of metformin use during docetaxel chemotherapy on prostate cancer specific and overall survival of diabetic patients with castration resistant prostate cancer[J]. J Urol, 2016, 28. pii: S0022-5347(16)31613-5. doi: 10.1016/j.juro.2016.10.069.[Epub ahead of print].
[30] Kapitein LC, Peterman EJ, Kwok BH, et al. The bipolar mitotic kinesin Eg5 moves on both microtubules that it crosslinks[J]. Nature, 2005, 435(7038): 114-118.
[31] Zhu L, Xiao F, Yu Y, et al. KSP inhibitor SB743921 inhibits growth and induces apoptosis of breast cancer cells by regulating p53, Bcl-2, and DTL[J]. Anticancer Drugs, 2016, 27(9): 863-872.
[32] Lu M, Zhu H, Wang X, et al. The prognostic role of Eg5 expression in laryngeal squamous cell carcinoma[J]. Pathology, 2016, 48(3): 214-218.
[33] Wood KW, Cornwell WD, Jackson JR. Past and future of the mitotic spindle as an oncology target[J]. Curr Opin Pharmacol, 2001, 1(4): 370-377.
[34] Purcell JW, Davis J, Reddy M, et al. Activity of the kinesin spindle protein inhibitor ispinesib(SB-715992)in models of breast cancer[J]. Clin Cancer Res, 2010, 16(2): 566-576.
[35] Good JA, Wang F, Rath O, et al. Optimized S-trityl-L-cysteinebased inhibitors of kinesin spindle protein with potent in vivo antitumor activity in lung cancer xenograft models[J]. J Med Chem, 2013, 56(5): 1878-1893.
[1] Anjing CHEN,Xun ZHANG. The new strategies of targeting SUMOylation in the treatment of glioma [J]. Journal of Shandong University (Health Sciences), 2020, 1(8): 88-94.
[2] Chuanzhu YAN,Wei WANG,Kunqian JI,Yuying ZHAO. Mitochondrial dysfunction and related brain diseases [J]. Journal of Shandong University (Health Sciences), 2020, 1(8): 34-41.
[3] ZHAO Zuohui, LI Cuiling, WANG Daoguang, WANG Fengqin, QU Hongyi, DING Sentai, GONG Jing, LÜ Jiaju, YANG Jinghua. Effect of MnSOD acetylation on the proliferation and apoptosis of clear cell renal cell carcinoma cell line 786-O [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2017, 55(9): 31-35.
[4] ZHAI Hongyun, ZHANG Denglu, WANG Guangjie, KONG Feng, CHENG Guanghui, ZHAO Shengtian. Effects of factors secreted by mouse embryonic stem cells on prostate cancer cells in vitro [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2015, 53(9): 8-12.
[5] DING Huan1, SUN Ying1, LI Xiao-qing2, LI Li1. Effect of PARP inhibitor combined with Gemcitabine or Docetaxel on the  proliferation of androgen-independent prostate cancer cell line PC3 [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2014, 52(1): 33-36.
[6] ZHENG Yi, JIANG Wei, JIN Xun-bo, WANG Mu-wen, ZHANG Yi-nan, XIA Qing-hua. Valproic acid induces autophagy and regulates the expression of  SPARCL1 protein in prostate cancer cells [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2013, 51(7): 32-35.
[7] GAO Feng-bin, SI Man-fei, LIU Yong-qing, NIU Lei-lei, YUAN Hui-qing. Retigeric acid B induced cell cycle arrest in human prostate cancer cells by upregulation of p21CIP1 [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2013, 51(12): 34-40.
[8] LI Xian-zhe1, SI Man-fei1,2, GUO Yan-xia1, YUAN Hui-qing1 . Differential expression and regulation of PDLIM4 in prostate cancer cells [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2013, 51(06): 34-39.
[9] YU Zhang-jian1, ZHANG Shi-bao1, LIU Qing-yong1, RUAN Xi-yun2, YANG Guang-xiao3, WANG Quan-ying3. Construction of a recombinant adenoassociated viral vector expressing SAC and its inhibition on CAM xenograft prostate cancer [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2012, 50(7): 41-.
[10] CHEN Weiguo1, LONG Huimin2, HOU Jianquan1, PU Jinxian1, YAN Chun yin1. Inhibitory effect of Gefitinib on hormone independent prostate cancer in vitro and in vivo [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2010, 48(1): 52-55.
[11] WANG Xiao-ling,KONG Feng,XU Ai-hui,JI Kai,CAI Jie,REN Kai,YUAN Hui-qing. Effect of sesquiterpenoids on proliferation activity of prostate cancer cells [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2007, 45(12): 1189-1192.
Viewed
Full text


Abstract

Cited
  Shared   
  Discussed   
No Suggested Reading articles found!
Copyright 2018 © Editorial office of Journal of Shandong University (Health Sciences)
Supported by Beijing Magtech Co.Ltd